Literature DB >> 1481872

Procollagen type I C-terminal extension peptide in predialysis chronic renal failure.

G Coen1, S Mazzaferro, P Ballanti, E Bonucci, F Bondatti, M Manni, M Pasquali, I Perruzza, D Sardella, A Spurio.   

Abstract

Collagen type 1 is the most abundant protein of bone. Serum levels of type 1 procollagen carboxy-terminal extension peptide (Procoll-1-C) may give a measure of the rate of synthesis of the collagen of bone and be therefore a marker of bone turnover. We have studied 38 patients with predialysis chronic renal failure; 14 of them were under long-term treatment with 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] for prevention of secondary hyperparathyroidism. In all patients a transiliac bone biopsy for histomorphometry and determination of dynamic parameters was performed following double tetracycline labeling. In addition serum Procoll-1-C, intact and C-terminal parathyroid hormone (PTH), osteocalcin and alkaline phosphatase were determined. In the patients not receiving 1,25(OH)2D3, serum levels of Procoll-1-C were higher than normal. Procoll-1-C did not correlate with any of the humoral parameters, including serum creatinine, nor with static histomorphometric parameters. Contrarily to osteocalcin, the collagen type 1 marker correlated significantly with all dynamic parameters. Treatment with 1,25(OH)2D3 was accompanied by lower levels of osteocalcin, iPTH (n.s.), osteoblastic surface and by normal levels of Procoll-1-C (p < 0.001, compared to untreated patients), without substantial change in bone formation parameters (bone formation rate). In conclusion Procoll-1-C in predialysis chronic renal failure is a marker of bone turnover unparalleled by other markers. 1,25(OH)2D3 administration is associated with lower serum levels of the peptide unaccompanied by a decrement of bone formation parameters, therefore with an apparently better utilization of collagen type 1 in the mineralization process.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1481872     DOI: 10.1159/000168453

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

Review 1.  Renale osteodystrophie.

Authors:  Daniel Cejka
Journal:  Wien Med Wochenschr       Date:  2013-05-09

2.  Comparison of Left Ventricular Hypertrophy, Fibrosis and Dysfunction According to Various Disease Mechanisms such as Hypertension, Diabetes Mellitus and Chronic Renal Failure.

Authors:  Yoon-Seok Koh; Hae-Ok Jung; Mahn-Won Park; Joo-Yeoul Baek; Sung-Gyu Yoon; Pum-Joon Kim; Sang-Hyun Ihm; Kiyuk Chang; Yong-Seog Oh; Ho-Joong Youn; Sang Hong Baek; Wook-Sung Chung; Ki-Bae Seung; Jae-Hyung Kim
Journal:  J Cardiovasc Ultrasound       Date:  2009-12-31

3.  Calcitonin and bisphosphonates treatment in bone loss after liver transplantation.

Authors:  M A Valero; C Loinaz; L Larrodera; M Leon; E Moreno; F Hawkins
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

4.  Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial.

Authors:  Madonna Salib; Sophie Girerd; Nicolas Girerd; Winfried März; Hubert Scharnagl; Ziad A Massy; Céline Leroy; Kévin Duarte; Hallvard Holdaas; Alan G Jardine; Roland E Schmieder; Bengt Fellström; Natalia López-Andrés; Patrick Rossignol; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2021-06-25       Impact factor: 6.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.